JERSEY CITY, NJ / ACCESSWIRE / November 4, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that one of its products, Xiongju Shangqing Tablet, has been included in the government essential drug procurement lists for nine Chinese provinces: Shanghai, Qinghai, Gansu, Hubei, Shanxi, Anhui, Sichuan, Jilin and Inner Mongolia. The combined population of these nine provinces is approximately 400 million, representing a significant potential market.
The Xiongju Shangqing Tablet is indicated for treatment of migraine, toothache and sore throat, as well as flu-related pain, fever and runny nose. Hebei Aoxing, the operating subsidiary of Aoxing Pharma, is one of only three pharmaceutical companies licensed to produce the Xiongju Shangqing Tablet in China.
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2015, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
CONTACT:
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
or
Asia IR-PR
Jimmy Caplan, 512-329-9505
jimmy@asia-irpr.com
or
Media Relations:
Asia IR-PR
Rick Eisenberg, 212-496-6828
rick@asia-irpr.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
